LP 0200
Alternative Names: IL-17A PPI; LP-0200Latest Information Update: 21 Jul 2022
Price :
$50 *
At a glance
- Originator LEO Pharma
- Class Antipsoriatics; Small molecules
- Mechanism of Action Interleukin 17 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Psoriasis
Most Recent Events
- 21 Jul 2022 Phase-I clinical trials in Psoriasis in Denmark (PO) (LEO Pharma pipeline, July 2022)
- 26 Mar 2021 LEO Pharma plans a phase I trial for Psoriasis (LEO pharma pipeline, December 2020)
- 23 Mar 2021 LP 0200 is available for licensing as of 23 Mar 2021. https://leo-pharma.com/partnership/what-are-we-looking-for-in-a-partnership